Medprin Regenerative Medical Technologies Future Growth
Future criteria checks 5/6
Medprin Regenerative Medical Technologies is forecast to grow earnings and revenue by 44.7% and 25.3% per annum respectively while EPS is expected to grow by 44.4% per annum.
Key information
44.7%
Earnings growth rate
44.4%
EPS growth rate
Medical Equipment earnings growth | 24.5% |
Revenue growth rate | 25.3% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 09 Nov 2023 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2025 | 377 | 105 | N/A | 154 | 1 |
12/31/2024 | 288 | 68 | N/A | 51 | 1 |
3/31/2024 | 244 | 48 | 60 | 104 | N/A |
12/31/2023 | 231 | 41 | 68 | 108 | N/A |
9/30/2023 | 202 | 31 | 20 | 89 | N/A |
6/30/2023 | 186 | 27 | -8 | 67 | N/A |
3/31/2023 | 202 | 37 | -30 | 70 | N/A |
1/1/2023 | 195 | 36 | -88 | 48 | N/A |
9/30/2022 | 190 | 43 | -80 | 66 | N/A |
6/30/2022 | 180 | 45 | -105 | 64 | N/A |
3/31/2022 | 159 | 41 | -103 | 58 | N/A |
1/1/2022 | 154 | 45 | -86 | 67 | N/A |
9/30/2021 | 145 | 46 | -76 | 56 | N/A |
6/30/2021 | 140 | 42 | -47 | 48 | N/A |
3/31/2021 | 137 | 43 | -38 | 46 | N/A |
12/31/2020 | 124 | 37 | -28 | 34 | N/A |
12/31/2019 | 113 | 28 | -5 | 31 | N/A |
12/31/2018 | 86 | -19 | -14 | 6 | N/A |
12/31/2017 | 54 | -19 | N/A | 6 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 301033's forecast earnings growth (44.7% per year) is above the savings rate (2.9%).
Earnings vs Market: 301033's earnings (44.7% per year) are forecast to grow faster than the CN market (24.2% per year).
High Growth Earnings: 301033's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: 301033's revenue (25.3% per year) is forecast to grow faster than the CN market (14.7% per year).
High Growth Revenue: 301033's revenue (25.3% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if 301033's Return on Equity is forecast to be high in 3 years time